If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Share News (CSRT)

  • There is currently no data for CSRT

Monday broker round-up UPDATE

Mon, 03rd Dec 2012 07:16
ARM Holdings: Exane BNP Paribas upgrades from neutral to buy.Ashtead Group: Bank of America starts with a target price of 460p and a buy recommendation.AstraZaneca: Berenberg raises target price from 3080p to 3100p; hold recommendation kept.Balfour Beatty: Investec reduces target price from 210p to 200p and keeps a sell recommendation.Berkeley Group: Northland Capital raises target price from 1650p to 1750p, while keeping a buy rating.Betfair Group: Exane BNP Paribas reduces target price from 1050p to 900p and maintains an outperform rating.Cape: Northland Capital reduces target price from 230p to 155p and maintains a reduce rating.Centrica: Citigroup upgrades to buy, while keeping its target price of 360p.Centurion Resources: HB Markets initiates with a speculative buy.Consort Medical: Jefferies raises target price from 730p to 880p and reiterates its buy recommendation.Dixons Retails: Deutsche Bank moves target price from 28p to 30p and reiterates a buy rating.Enterprise Inns: Deutsche Bank raises target price from 105p to 135p and upgrades to buy.First Group: Barclays reduces target price from 210p to 190p and reiterates an equal weight rating.GlaxoSmithKline: Berenberg reduces target price from 1610p to 1530p; buy recommendation remains unchanged.Go-Ahead Group: Barclays reduces target price from 1450p to 1380p, while maintaining an equal weight rating.International Ferro Metals: Numis reduces target price from 35p to 30p and keeps a buy recommendation.Marston's: Barclays raises target price from 120p to 140p; while reiterating an overweight rating.National Express: Barclays reduces target price from 210p to 190p; equal weight rating unchanged.Pay Point: Jefferies initiates with a target price of 1020p and a buy recommendation.Rio Tinto: Canaccord Genuity raises target price from 3750p to 3850p, maintaining a buy recommendation.Royal Dutch Shell: Deutsche Bank downgrades to hold; target price of 2475p remains unchanged.RSA Insurance Group: Deutsche Bank raises target price from 120p to 136p and upgrades to buy.Scapa Group: Numis raises target price from 77p to 80p; buy rating remains unchanged.Schroders: Bank of America upgrades from neutral to buy.Segro: Societe Generale reduces target price from 290p to 280p and keeps its buy recommendation.Stagecoach Group: Barclays reduces target price from 340p to 335p and keeps an overweight rating.SThree: UBS reduces target price from 350p to 335p and maintains a buy rating. Numis downgrades to add and keeps a target price of 350p.St. Modwen Properties: Peel Hunt reduces target price from 235p to 250p; buy recommendation maintained.Touchstone Gold: Northland Capital reduces target price from 18.60p to 16.60p and keeps its buy recommendation.Tullow Oil: HSBC upgrades to neutral; target price of 1381p unchanged.UBM: Investec downgrades to hold, keeping a target price of 745p.Unilever: Panmure Gordon raises target price from 2500p to 2600p and maintains its buy recommendation. Investec raises target price from 2300p to 2400p, while reiterating a hold rating.Work Group: Merchant Securities reduces target price from 10.50p to 7.50p and reiterates a hold recommendation.

Related News

LONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears
14 hours ago

LONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears

(Alliance News) - European stocks soared on Thursday as weaker than expected US jobs figures dampened market worries of a near-term interest rate hike...

Hutchmed drug approved in China for advanced gastric cancer
16 hours ago

Hutchmed drug approved in China for advanced gastric cancer

(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer wi...

CSRT.L News

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition
17 Feb 2020

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition

Monday broker round-up
10 Feb 2020

Monday broker round-up

(Sharecast News) - Consort Medical: RBC Capital Markets upgrades to sector performer with a target price of 1,010p.

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional
4 Feb 2020

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional

Recipharm To Make No Further Changes To Consort Medical Offer
29 Jan 2020

Recipharm To Make No Further Changes To Consort Medical Offer

Recipharm To Make No Further Changes To Consort Medical Offer

Recipharm Extends Consort Medical Offer Deadline To February 4
24 Jan 2020

Recipharm Extends Consort Medical Offer Deadline To February 4

Recipharm Extends Consort Medical Offer Deadline To February 4

Recipharm Buys 10% Of Takeover Target Consort Medical
22 Jan 2020

Recipharm Buys 10% Of Takeover Target Consort Medical

Recipharm Buys 10% Of Takeover Target Consort Medical

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle
14 Jan 2020

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle

Friday broker round-up
10 Jan 2020

Friday broker round-up

(Sharecast News) - Polymetal International: Berenberg upgrades to buy with a target price of 1,480p.